Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 7, 2014; 20(13): 3431-3442
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3431
Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging
Verónica Saludes, Victoria González, Ramon Planas, Lurdes Matas, Vicente Ausina, Elisa Martró
Verónica Saludes, Victoria González, Lurdes Matas, Vicente Ausina, Elisa Martró, Microbiology Service, Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol (Universitat Autònoma de Barcelona), 08916 Badalona, Spain
Verónica Saludes, Victoria González, Lurdes Matas, Elisa Martró, CIBER Epidemiología y Salud Pública (CIBERESP), 08003 Barcelona, Spain
Victoria González, Centre for Epidemiological Studies on HIV/STI in Catalonia (CEEISCAT)-ICO, 08916 Badalona, Spain
Ramon Planas, Liver Unit, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Spain
Ramon Planas, CIBER Enfermedades Hepáticas y Digestivas (CIBEREHD), 08036 Barcelona, Spain
Vicente Ausina, CIBER Enfermedades Respiratorias (CIBERES), 07110 Bunyola, Spain
Author contributions: Martró E conceived the topic; Saludes V, González V and Martró E reviewed the literature and wrote the manuscript; Planas R, Matas L and Ausina V provided overall intellectual input into the review’s topic and edited the manuscript; all authors approved the final version to be published.
Supported by A Miguel Servet contract No. MS09/00044 funded by FIS-ISCIII (Spanish Government) to Martró E; grant PI10/01734 within the “Plan Nacional de I+D+I” and co-financed by “ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional” (FEDER) to González V, Saludes V, Martró E
Correspondence to: Elisa Martró, PhD, Researcher in the National Health System, Microbiology Service, Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Hospital Universitari Germans Trias i Pujol (Universitat Autònoma de Barcelona), Ctra. del Canyet s/n, 08916 Badalona, Spain. emartro.igtp.germanstrias@gencat.cat
Telephone: +34-934-978894 Fax: +34-934-978895
Received: September 27, 2013
Revised: December 7, 2013
Accepted: March 6, 2014
Published online: April 7, 2014
Processing time: 188 Days and 16.4 Hours
Abstract

Hepatitis C virus (HCV) infection represents a major public health issue. Hepatitis C can be cured by therapy, but many infected individuals are unaware of their status. Effective HCV screening, fast diagnosis and characterization, and hepatic fibrosis staging are highly relevant for controlling transmission, treating infected patients and, consequently, avoiding end-stage liver disease. Exposure to HCV can be determined with high sensitivity and specificity with currently available third generation serology assays. Additionally, the use of point-of-care tests can increase HCV screening opportunities. However, active HCV infection must be confirmed by direct diagnosis methods. Additionally, HCV genotyping is required prior to starting any treatment. Increasingly, high-volume clinical laboratories use different types of automated platforms, which have simplified sample processing, reduced hands-on-time, minimized contamination risks and human error and ensured full traceability of results. Significant advances have also been made in the field of fibrosis stage assessment with the development of non-invasive methods, such as imaging techniques and serum-based tests. However, no single test is currently available that is able to completely replace liver biopsy. This review focuses on approved commercial tools used to diagnose HCV infection and the recommended hepatic fibrosis staging tests.

Keywords: Hepatitis C virus; Diagnosis; Real-time polymerase chain reaction; Serology; Hepatitis C virus-RNA quantification; Hepatitis C virus genotyping; Hepatic fibrosis staging

Core tip: About 150 million people are chronically infected with hepatitis C virus (HCV) worldwide, making them at risk for cirrhosis, hepatocellular carcinoma and end-stage liver disease. Recent advances in hepatitis C therapy may bring the opportunity of eradicating this infection. However, ongoing HCV transmission, under-diagnosis of HCV-infected persons, and difficulties in accessing treatment remain great challenges that require public health responses. In this review, we focus on diagnostic methods used to control HCV infection, including laboratory and point-of-care tests. We also discuss available non-invasive methods to assess liver fibrosis, as the severity of liver disease has important implications in the prognosis and treatment of hepatitis C.